[PRACTICE NOTE] Your Call Plan Isn’t the Problem. Your Customer Context Is.

Why healthcare professionals now judge pharmaceutical engagement against the best experiences in their lives, and what that means for the future of commercial leadership.

When commercial performance falters, the reflex inside many pharmaceutical organizations is to adjust the machinery of field execution. Leaders revisit call plans, recalibrate targeting models, and increase the volume of activity in the hope that more precision or more frequency will restore momentum. For decades this system has been treated as the central instrument of commercial performance, determining which physicians are prioritized, how frequently representatives engage, and how resources are deployed across territories.

Yet the growing gap between commercial effort and commercial impact suggests a deeper issue. The problem is rarely the design of the call plan itself. It is the context in which healthcare professionals now operate. Physicians are navigating increasingly complex clinical, administrative, and informational environments, and that evolving reality now shapes prescribing behavior far more than the cadence of promotional interactions.

What many organizations are experiencing is a widening Customer Context Gap. Commercial systems were designed for a time when prescribing decisions could be influenced primarily through promotional interaction and product information. Today physicians operate inside a far more complex reality shaped by administrative burden, reimbursement constraints, digital information overload, and growing expectations for seamless support across the entire care journey. In this environment the physician’s decision is influenced not only by clinical evidence but also by how easily a therapy fits into the practical realities of care delivery. When commercial models remain anchored in promotional activity while the customer’s context has fundamentally changed, even the most disciplined call plan struggles to deliver the outcomes it was designed to produce.

Closing this gap requires a different way of thinking about commercial performance. The question is no longer how to optimize promotional activity but how to align the organization around the real journeys through which physicians help patients receive therapy. Prescribing decisions unfold within complex sequences of clinical evaluation, reimbursement navigation, patient readiness, and ongoing support. When commercial strategy is designed around these journeys rather than isolated interactions, the role of the field force begins to evolve. Representatives are no longer positioned primarily as messengers of information but as partners in removing barriers that slow care. Organizations that recognize this shift begin redesigning their commercial systems accordingly, aligning field engagement, digital support, access programs, and patient services around the same goal: helping healthcare professionals help patients move from clinical intent to successful treatment.

From Promotional Activity to Customer Journeys

The pharmaceutical industry has historically organized commercial activity around the moment of promotion. Call plans, targeting models, and message sequencing were designed to influence prescribing behavior primarily through informational engagement with healthcare professionals. While this model brought structure and scale to commercial operations, it reflects an earlier era in which the path from clinical awareness to prescribing action was comparatively linear.

Today the journey is far more complex. Physicians must navigate an intricate landscape of clinical evidence, treatment guidelines, payer requirements, prior authorization processes, patient affordability concerns, and adherence challenges. Prescribing a therapy is no longer a single decision point. It is the beginning of a chain of events that determines whether a patient ultimately receives and remains on treatment.

This is why the commercial conversation must expand beyond the traditional moment of prescription to encompass three interconnected journeys. The first is the Path-to-Prescribe, where scientific evidence, clinical education, and confidence in the therapy shape the physician’s willingness to recommend treatment. The second is the Path-to-Fulfill, where access, affordability, patient readiness, and operational support determine whether that recommendation ultimately becomes therapy in the patient’s hands. The third is the Path-to-Adhere, where ongoing patient support, monitoring, and engagement determine whether patients remain on therapy long enough to realize the intended clinical benefit.

Science drives the Path to Prescribe, where evidence, clinical education, and confidence in the therapy shape the physician’s willingness to recommend treatment. Experience shapes the Path to Fulfill, where access, affordability, and patient readiness determine whether that recommendation becomes therapy in the patient’s hands. Sustained outcomes depend on the Path to Adhere, where ongoing support, monitoring, and engagement ensure patients remain on therapy long enough to realize its intended clinical benefit. When commercial organizations focus almost exclusively on the first while leaving the latter journeys fragmented and burdened, a significant portion of therapeutic value is lost between intention and impact. In many therapeutic areas, the result appears in the persistent gap between prescriptions written, prescriptions filled, and therapies sustained—gaps that reflect not a failure of science but a failure of system design.

Recognizing these three journeys shifts the unit of focus from promotional activity to the real-world pathways through which care is delivered. It reframes the role of the field force, the purpose of digital engagement, and the design of patient support programs around a single objective: reducing the friction that stands between clinical intent, treatment initiation, and sustained patient outcomes.

Customer Context Is the New Commercial Variable

For much of the pharmaceutical industry’s history, commercial performance was largely explained by a familiar set of variables. Product efficacy, clinical differentiation, promotional reach, and sales force execution determined the trajectory of most brands. When performance lagged, leaders adjusted those levers by refining segmentation, optimizing targeting, and recalibrating call plans.

Today those traditional levers still matter, but they no longer explain commercial outcomes on their own. A far more powerful variable has entered the equation: customer context.

HCPs now operate within an environment defined not only by clinical complexity and administrative burden but also by rising expectations shaped by their experiences outside healthcare. Physicians are also consumers. In their personal lives they interact daily with companies such as Apple, Amazon, Tesla, and Netflix that anticipate their needs, remove friction, and simplify complex processes through thoughtful design. These experiences quietly reset the benchmark for competence, responsiveness, and respect for their time.

When those same physicians step into their clinical roles, they do not shed those expectations. They carry them with them. The contrast between the seamless orchestration of their consumer experiences and the fragmented systems surrounding many healthcare interactions becomes difficult to ignore. What once felt acceptable now feels unnecessarily burdensome.

This dynamic represents the Consumer-Grade Imperative. Healthcare professionals increasingly evaluate pharmaceutical engagement not against other pharmaceutical companies but against the best experiences they encounter anywhere in their lives. In this environment even a clinically superior therapy can struggle if the surrounding system makes it difficult to initiate treatment, navigate reimbursement, or support patient adherence.

Customer context therefore becomes the new commercial variable. It determines whether scientific differentiation translates into practical adoption. It shapes whether prescribing intent becomes therapy initiation and whether therapy initiation becomes sustained patient outcomes.

Call plans were designed to manage activity. Customer context requires organizations to manage journeys.

The Field Force in the Era of Customer Context

Recognizing customer context as the defining commercial variable inevitably reshapes how the role of the field force is understood. For decades the pharmaceutical sales representative has been positioned primarily as the carrier of scientific information. Call plans optimized the frequency and sequencing of these interactions to ensure that physicians received consistent messaging.

That role does not disappear, but the environment surrounding it has changed profoundly. Physicians today are navigating administrative burden, payer complexity, digital information overload, and increasing time pressure. In this environment they are not simply seeking more information. They are seeking clarity, simplicity, and support that helps them navigate the complexity surrounding treatment decisions.

This shift transforms the representative from a messenger of information into something far more valuable: a partner in removing friction from the care journey. Conversations move beyond repeating clinical claims toward understanding the practical barriers that physicians and their teams face as they attempt to initiate and sustain therapy for patients.

The most effective field forces are therefore supported by commercial systems designed around journeys rather than activities. Representatives are equipped not only with scientific messaging but with the insight and coordination required to address obstacles across prescribing, reimbursement, and patient support. Field engagement becomes a catalyst for problem solving rather than simply a vehicle for promotion.

From Call Plans to Customer-Aligned Commercial Systems

If customer context has become the defining commercial variable, then the systems designed to support the field must evolve accordingly.

The traditional call plan was built to manage activity. It provided structure for how frequently physicians were engaged, how territories were covered, and how resources were deployed. Yet activity alone does not determine whether therapies ultimately reach patients. What determines impact is whether the commercial system surrounding the physician reduces or increases the burden of delivering care.

A customer-aligned commercial system begins with the journeys through which physicians help patients move from diagnosis to treatment and beyond. Marketing clarifies the scientific story. Sales provides trusted relationships and real-time understanding of physician needs. Access teams simplify reimbursement pathways. Patient support programs reduce administrative burden. Digital engagement reinforces and extends human interaction.

The result is a commercial system that operates less like disconnected functions and more like an integrated network designed to help physicians help patients. This is the essence of Customer Excellence. It aligns the entire commercial enterprise around the real-world context in which care is delivered. The problem was never the call plan. The problem was the context.

Key Takeaways

Commercial performance in pharma organizations has traditionally been managed through field execution mechanics, yet the effectiveness of those mechanics increasingly depends on how well they reflect the real-world context in which physicians operate.
Customer context has become the most pivotal commercial variable as administrative burden, payer complexity, and consumer-grade expectations reshape how prescribing decisions are made.
HCPs now evaluate pharmaceutical engagement against the best experiences they encounter anywhere in their lives, raising the standard for clarity, responsiveness, and ease.
Optimizing promotional activity alone is no longer sufficient. Commercial success depends on reducing friction across the journeys physicians navigate as they move patients from diagnosis to treatment.
Customer Excellence represents the structural response, aligning marketing, sales, access, digital engagement, and patient support around the real journeys of care delivery.

Diagnostic Questions to Consider

Are we optimizing the activity of our field force, or designing commercial systems that support the real journeys physicians navigate to help patients receive therapy?
How well do we understand the administrative, reimbursement, and operational barriers physicians encounter after they decide to prescribe a therapy?
Do our commercial systems reduce the burden placed on physicians and their staff, or unintentionally add to the complexity of care delivery?
Are we benchmarking our engagement against other pharma companies, or against the best experiences physicians encounter in their lives as consumers?
Have our investments in digital platforms simplified the physician’s experience, or multiplied the number of disconnected interactions they must manage?
Are we still managing performance through activity metrics alone, or beginning to understand the context that ultimately determines whether therapies reach patients?

Closing Reflection

The pharma and life sciences industry has spent decades refining the mechanics of field execution. Call plans, segmentation models, and targeting systems brought structure and discipline to commercial organizations. Yet the environment surrounding physicians has evolved far more rapidly than the systems built to support them.

Healthcare professionals now operate in a world defined by consumer-grade expectations for clarity, responsiveness, and ease. When the experience of engaging with a pharmaceutical company fails to reflect those expectations, the contrast becomes impossible to ignore.

Organizations that recognize this shift will redesign their commercial systems around the realities of modern care delivery. They will move beyond managing activity and toward understanding the context in which physicians help patients receive treatment. In doing so they will close the gap between scientific innovation and real-world impact.

Your breakthrough science deserves experiences worthy of it. Together, we turn customer excellence into real-world impact.

About the Author

Wayne Simmons is a hands-on commercial excellence architect and founder of The Customer Excellence Agency, where he partners with pharmaceutical and life sciences leaders to turn customer-centric ambition into durable commercial advantage. He previously served as Global Customer Excellence Lead within Pfizer’s Chief Marketing Organization and has held leadership roles with Bayer Pharmaceuticals and The Ritz-Carlton Leadership Center. Wayne writes The Customer-Centric Marketer newsletter and is the author of The Customer Excellence Enterprise: A Playbook for Creating Customers for Life.

The Customer Excellence Agency: Advancing the Pursuit of Excellence in Service of Science.

< Older Post

Newer Post >

[PRACTICE NOTE] The Next Chapter of Commercial Excellence in Pharma

By Wayne Simmons • March 15, 2026

Why Customer Excellence is emerging as the discipline that turns scientific innovation into real-world impact. Pharmaceutical science has never been stronger. Pipelines are more diverse, clinical development more precise, and manufacturing more advanced than at any point in history. Yet amid this extraordinary progress the industry faces a defining paradox. Scientific excellence has accelerated dramatically, while the experiences through which that science reaches physicians and patients have not kept pace. The next chapter of commercial excellence will not be won by companies that merely communicate their science more efficiently. It will belong to organizations that deliver it more meaningfully. The companies that lead the next era of healthcare will treat customer experience with the same rigor as clinical efficacy, ensuring that every engagement becomes living proof of their science, their purpose, and their credibility. For decades the pharmaceutical industry has set the evidentiary standard for science and the trust standard for its brands. What now emerges as the next frontier is an experiential standard capable of matching both. Only when the experience of engaging with a company reflects the same precision, credibility, and consistency that govern its science will the full value of innovation reach the people it is intended to serve. This evolution begins with Customer Excellence , the discipline that unites marketing, sales, and launch excellence into a coherent commercial operating system capable of earning both permission and preference. ⸻ From Science as Foundation to Experience as Fulfillment Science remains the foundation and heartbeat of the pharmaceutical enterprise. It drives the Path-to-Prescribe, where evidence, education, and clinical outcomes shape confidence and influence decisions. Yet even the most extraordinary science cannot fulfill its promise unless it reaches patients through systems that are intuitive, accessible, and human. Experience now headlines the Path-to-Fulfillment, the continuum of interactions that determines whether prescribed therapies ultimately translate into outcomes. Across this journey friction, administrative burden, and fragmented processes often erode impact. Clinical innovation can demonstrate efficacy, but experience determines whether that efficacy becomes reality. The journey from lab to life depends on what occurs before, during, and after the moment of prescription. Before prescribing, healthcare professionals form impressions of credibility, clarity, and relevance. At the point of decision, trust and confidence determine uptake. Afterward, education, access, and patient support sustain adherence and belief. In some therapeutic areas as many as half of prescriptions go unfulfilled. This is rarely a failure of science. It is more often a failure of system design, where burden-heavy and friction-heavy journeys make it difficult for healthcare professionals to initiate and sustain therapy for their patients. Pharma has long set the benchmark for scientific evidence and brand trust. What is now required is an experiential standard equal to those same heights, ensuring that engagement with the company feels as credible, coherent, and confidence-inspiring as the science itself. Science drives the Path-to-Prescribe. Experience headlines the Path-to-Fulfillment. Together they define the new frontier of Customer Excellence. ⸻ Why Transformation Is No Longer Enough Transformation has become the default response to nearly every commercial challenge. Digital transformation, omnichannel transformation, and now AI transformation have each promised to close the gap between companies and their customers. Yet despite billions invested across platforms, data systems, and engagement technologies, the experiences delivered to healthcare professionals often remain inconsistent, impersonal, and disconnected. The issue is not intent but orientation. Transformation modernizes tools, yet rarely challenges the mental models that define success. Organizations become more efficient at executing familiar patterns rather than reimagining how value should be delivered. Pharma does not require another transformation initiative. What it requires is a disciplined shift in thinking that questions the orthodoxy of activity metrics, channel proliferation, and functional isolation while restoring coherence and humanity to how the industry delivers its science to the world. ⸻ Customer Excellence as a Rebellion Customer Excellence represents that shift. It is a disciplined and systemic redefinition of how value is created, delivered, and sustained. Rather than measuring progress through scale and speed alone, it positions coherence, trust, and ease as the true measures of commercial excellence. This shift is not a rebellion against compliance but against complacency. It challenges leaders to move beyond optimization toward orchestration, building organizations where the quality of engagement reflects the quality of the science itself. ⸻ The Seven Shifts Defining the Discipline The seven shifts form the architecture of Customer Excellence, uniting marketing, sales, and launch excellence into a single human-centered model for sustainable growth. Shift 1. From Tangible to Intangible Value Exchange Customers increasingly evaluate companies through intangible dimensions such as trust, relevance, and ease. Experiential Commerce has elevated these factors from soft considerations to structural drivers of enterprise value. Shift 2. From Campaign-Centric to Customer-Centric Journeys Marketing can no longer rely on episodic campaigns alone. Value is created across continuous journeys where engagement extends far beyond the initial promotional moment. Shift 3. Experience as a Third Pillar of Value Product and brand may attract attention, but experience determines whether relationships endure. Organizations that integrate experience alongside product and brand create a far more resilient value proposition. Shift 4. From Transactions to Relationships Customer health must be measured over time. Longitudinal relationships built on trust ultimately drive sustainable commercial performance. Shift 5. From Funnel to Flywheel Growth no longer ends at conversion. Customer Excellence transforms disconnected interactions into a compounding cycle of engagement, trust, and expansion. Shift 6. From Neutral Interactions to Brand-Defining Moments Every interaction communicates brand character. Thoughtfully designed experiences become evidence of reliability and partnership. Shift 7. From Vertical Silos to Horizontal Journeys Customers experience companies horizontally across journeys, not vertically through internal functions. Customer Excellence realigns organizations to reflect this reality. ⸻ From Rebellion to System The seven shifts describe how pharmaceutical organizations can close the gap between scientific mastery and the lived experiences that bring that science to life. Customer Excellence does not replace Marketing Excellence, Sales Excellence, or Launch Excellence. It integrates them. Together these disciplines form a unified Customer-Aligned Commercial Operating System capable of delivering both differentiation and trust. Within this system marketing defines the story, sales delivers the experience, launch orchestrates the moment, and Customer Excellence ensures that what is promised is consistently delivered. This is the next chapter of commercial excellence in pharma. It moves the industry beyond transformation toward orchestration, beyond scale toward coherence, and beyond message toward meaning. Science drives the Path-to-Prescribe. Experience headlines the Path-to-Fulfillment. Customer Excellence unites them both. Science earns permission. Experience earns preference. Customer Excellence earns both. ⸻ Key Takeaways The future of differentiation in healthcare is experiential. Scientific innovation remains essential, but the experiences surrounding therapies increasingly determine whether that innovation achieves its intended impact. Customer Excellence represents the structural response to this shift. By integrating marketing, sales, launch excellence, and service functions into a coherent operating system, organizations can translate scientific value into lived value. Trust is no longer assumed simply because a therapy demonstrates clinical efficacy. It is built through the design, coherence, and consistency of the experiences that surround prescribing, access, and patient support. Transformation initiatives may modernize tools, yet genuine change occurs when organizations replace compliance-driven thinking with a deeper conviction about the centrality of the customer. Science earns permission through evidence, while experience earns preference through delivery. Together they form the foundation of enduring growth in the era of Experiential Commerce. ⸻ Diagnostic Questions to Consider As the commercial model evolves, leadership teams must confront several difficult questions. Are we still benchmarking our engagement against other pharmaceutical companies, or against the best experiences healthcare professionals encounter in their everyday lives? Where does friction persist across the real journeys of prescribing, access, and patient adherence, and how clearly do we understand the barriers preventing clinical intent from translating into treatment? Do our commercial systems reinforce the promise of our science and brand, or do they introduce complexity that quietly undermines them? Have our investments in digital platforms, omnichannel engagement, and artificial intelligence reduced the cognitive burden on healthcare professionals, or simply multiplied the number of touchpoints they must navigate? Are we organized around internal functions and campaigns, or around the journeys through which physicians and patients actually experience our therapies? Most importantly, are we building organizations that aspire to be customer-centric, or enterprises that are structurally designed to deliver customer excellence? Closing Reflection The pharmaceutical industry has mastered the science of discovery and the discipline of evidence. The next era of leadership will belong to companies that apply that same rigor to the experiences through which science reaches the world. When organizations align their commercial systems with the realities of modern customer expectations, innovation no longer struggles in the final mile between prescription and patient care. Instead it arrives with clarity, coherence, and confidence. Your breakthrough science deserves experiences worthy of it. Together, we turn customer excellence into real-world impact. About the Author Wayne Simmons is a customer excellence strategist and founder of The Customer Excellence Agency, where he partners with pharmaceutical and life sciences leaders to turn customer-centric ambition into durable commercial advantage. He previously served as Global Customer Excellence Lead within Pfizer’s Chief Marketing Organization and has held leadership roles with Bayer Pharmaceuticals and The Ritz-Carlton Leadership Center. Wayne writes The Customer-Centric Marketer newsletter and is the author of The Customer Excellence Enterprise: A Playbook for Creating Customers for Life. The Customer Excellence Agency: Advancing the Pursuit of Excellence in Service of Science.

Pharma commercial engines have reached unprecedented sophistication in generating prescribing intent

[PRACTICE NOTE] Journey Operations for Field Excellence

By Wayne Simmons • February 23, 2026

Pharma commercial engines have reached unprecedented sophistication in generating prescribing intent, yet a persistent structural gap remains between conviction and realized patient and commercial impact. The issue is not selling effectiveness.

[ABOUT] Advancing Human Health through The Pursuit of Excellence in Service of Science™

January 9, 2026

The Founding Philosophy of The Customer Excellence Agency Founded on the conviction that scientific brilliance only becomes human impact when excellence is engineered into leadership, culture, and experience delivery. This is a philosophy of rigor, responsibility, and reverence for the people science exists to serve.